Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide for adult ...
A new case report published in Annals of Internal Medicine describes a novel approach for treating fibrosing mediastinitis ...
At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) ...
As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.
Incyte Biosciences Japan G.K. (INCY) on Monday reported the approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi (tafasitamab) in combination with rituximab and lenalidomide ...
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...
The top 5 most-viewed videos of 2025 explored a range of topics, including data presented at major medical meetings, health ...
Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback